


BEST AVAILABLE COPY



TITLE: SOLUTION FORMULATIONS OF SIROLIMUS...
FIRST NAMED INVENTOR: Robert Falotico
APP#:
ATTY: Carl J. Evens
DOCKET #: CRD-5073
CUST. #: 000027777















TITLE: SOLUTION FORMULATIONS OF SIROLIMUS...
FIRST NAMED INVENTOR: Robert Falotico
APP#:
ATTY: Carl J. Evens TEL. #: 732-524-2518
DOCKET #: CRD-5073 CUST. #: 000027777 4/51 → 50% rapamycin → 30% rapamycin ■ 9% rapamycin 25 20 Time, hours 10 - 10 fraction 0.100—drug released 0.080— 0.020+ 0.0000 0.040 0.060 0.120 0.200_{1} 0.180 0.160 0.140

Release of Drug from FC-2261Q

F/G. 5

5/51



6/51









FIG. 8














9/51

FIG. 14 316 *302* 306 -312 304 310

FIG. 15

308




FIG. 16




FIG. 17




FIG. 18




FIG. 19





FIG. 20






FIG. 22







FIG. 23











FIG. 28






FIG. 30




FIG. 31





FIG. 32





19/51


FIG. 33





FIG. 34



















25/51

, nob










FIG. 49

27/51







FIG. 50


28/51









31/51



32/51



33/51



34/51







FIG. 57







37/51




F/G. 6(






F/G. 62



41/51




F/G. 64

No Etoposide

340.04 nM Etoposide 452.3 nM Etoposide 601.5 nM Etoposide 800 nM Etoposide

Log [Sirolimus (M)]


Inhibition of CA-SMC proliferation by sirolimus and etoposide (14 April 2003)



43/51

FIG. 66


Inhibition of CA-SMC proliferation by Panzem



44/51


FIG. 67

Inhibition of CA-SMC proliferation by sirolimus



*1*G. 68

Inhibition of CA-SMC proliferation by Sirolimus and Panzem



Panzem 9.018 uM Panzem 2.71 uM


Panzem 0.813 uM

Panzem 30.03 uM

Panzem 100 uM

No Panzem

46/51



Concentration (nM)

FIG. 70





FIG. 71






FIG. 72B





FIG. 72C



50/51

FIG. 73A






FIG. 73B





This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.